In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

CANCELLED - Are there differences in the outcomes of ischemic and non-ischemic cardiomyopathy in the current era?

Session Patient management - From oral treatment to transplant

Speaker Raed Odeh

Congress : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Heart Failure with Reduced Ejection Fraction
  • Session type : Rapid Fire Abstracts
  • FP Number : 1550

Authors : R Odeh (Riyadh,SA), RO Odeh (Riyadh,SA), MK Alkhateeb (Riyadh,SA), MM Almallah (Riyadh,SA), AA Ahmad (Riyadh,SA), AH Ardah (Riyadh,SA)


R Odeh1 , RO Odeh1 , MK Alkhateeb1 , MM Almallah1 , AA Ahmad1 , AH Ardah1 , 1King Abdulaziz Medical City - Riyadh - Saudi Arabia ,


There has been conflicting evidence on whether the outcomes of ischemic (ICM)  and non ischemic (NICM) exit. While older studies suggested the ICMP have worse outcomes, recent data suggest that the outcomes may be the same. The aim of this analysis is to explore the differences between ICM and NICMP in a well-treated contemporary cohort with heart failure with reduced ejection fraction (HFrEF).

A post hoc analysis of 2,805 (HFrEF) patients (Mean age 57.4, 70% females) were included. ICMP was defined HFrEF in the presence of obstructive coronary artery disease or myocardial infarction. Patients were followed up for a median duration of 4.4 years for all cause mortality.

A total of 1,675 patients had ICM while 1,130 patients had NICMP. Patients with ICMP were older, more often females, with higher prevalence of hypertension, diabetes, and dyslipidemia. NICMP patient had lower ejection fraction (33.6 ± 8.7 vs. 31.5 ± 11.1, p= <0.0001). Patients with NICMP were more often treated with beta blocker and aldactone, with no differences in ACEI/ARB.  After a median follow-up duration of 4.4 years, 436 patients died (147(14.7%) in the NICMP and 289 (18.86%)in the ICMP). After adjusting for confounders, including differences in medical therapy, ICMP was associated with increased risk of all-cause mortality (Hazarad ratio 1.62, 95% CI 1.32-2.04)

In the current era, ischemic cardiomyopathy continues to be associated with worse outcomes. This may be partially attributed to differences in medical therapies’.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are